Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia
Acute Myeloid Leukemia (AML) is an aggressive myeloid malignancy associated with high
mortality rates (less than 30% 5-year survival). Despite advances in our understanding of the …
mortality rates (less than 30% 5-year survival). Despite advances in our understanding of the …
Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia
M Aiba, A Shigematsu, T Suzuki, T Miyagishima - Annals of Hematology, 2023 - Springer
Venetoclax (VEN) is now widely used in the treatment of acute myelogenous leukemia
(AML) in elderly patients who are not eligible for intensive remission induction therapy …
(AML) in elderly patients who are not eligible for intensive remission induction therapy …
[HTML][HTML] MRD-directed and risk-adapted individualized stratified treatment of AML
Y Zhao, H Guo, Y Chang - Chinese Journal of Cancer Research, 2023 - ncbi.nlm.nih.gov
Measurable residual disease (MRD) has been widely recognized as a biomarker for deeply
evaluating complete remission (CR), predicting relapse, guiding pre-emptive interventions …
evaluating complete remission (CR), predicting relapse, guiding pre-emptive interventions …
[HTML][HTML] Curcumin attenuates Adriamycin-resistance of acute myeloid leukemia by inhibiting the lncRNA HOTAIR/miR-20a-5p/WT1 axis
JM Liu, M Li, W Luo, HB Sun - Laboratory investigation, 2021 - Elsevier
Acute myeloid leukemia (AML) is a common subtype of leukemia, and a large proportion of
patients with AML eventually develop drug resistance. Curcumin exerts cancer suppressive …
patients with AML eventually develop drug resistance. Curcumin exerts cancer suppressive …
Discovery of a novel CIP2A variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias
E Mäkelä, K Pavic, T Varila, U Salmenniemi… - Clinical Cancer …, 2021 - AACR
Purpose: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that
inhibits the tumor suppressor PP2A-B56α. However, CIP2A mRNA variants remain …
inhibits the tumor suppressor PP2A-B56α. However, CIP2A mRNA variants remain …
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic …
A Candoni, F De Marchi, ME Zannier, D Lazzarotto… - Leukemia Research, 2017 - Elsevier
We analyzed the outcome of allogeneic stem cell transplantation (allo-SCT) in acute myeloid
leukemia (AML) patients according to molecular Minimal Residual Disease (MRD) status …
leukemia (AML) patients according to molecular Minimal Residual Disease (MRD) status …
Wilms tumor 1 expression at diagnosis correlates with genetic abnormalities and polymorphism but is not independently prognostic in acute myelogenous leukemia: a …
D Hidaka, M Onozawa, J Hashiguchi… - … Myeloma and Leukemia, 2018 - Elsevier
Background The prognostic effect of Wilms tumor 1 (WT1) expression at the diagnosis of
acute myelogenous leukemia (AML) has been controversial. The aim of the present study …
acute myelogenous leukemia (AML) has been controversial. The aim of the present study …
Arpp19 promotes Myc and Cip2a expression and associates with patient relapse in acute myeloid leukemia
E Mäkelä, E Löyttyniemi, U Salmenniemi, O Kauko… - Cancers, 2019 - mdpi.com
Disease relapse from standard chemotherapy in acute myeloid leukemia (AML) is poorly
understood. The importance of protein phosphatase 2A (PP2A) as an AML tumor suppressor …
understood. The importance of protein phosphatase 2A (PP2A) as an AML tumor suppressor …
CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand?
D Damiani, M Tiribelli - Biomedicines, 2024 - mdpi.com
Despite recent advances, the prognosis of acute myeloid leukemia (AML) remains
unsatisfactory due to disease recurrence and the development of resistance to both …
unsatisfactory due to disease recurrence and the development of resistance to both …
[HTML][HTML] Prognostic significance of Wilms' tumor gene 1 expression in children with B-cell precursor acute lymphoblastic leukemia
Y Xue, Y Wang, L Zhang, A Lu, Y Jia, Y Zuo… - Frontiers in …, 2024 - frontiersin.org
Introduction The prognostic role of Wilms' tumor 1 (WT1) gene expression at diagnosis in
children with B cell precursor acute lymphoblastic leukemia (BCP-ALL) is still controversial …
children with B cell precursor acute lymphoblastic leukemia (BCP-ALL) is still controversial …